A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2027-11-15
Target enrollment:
Participant gender:
Summary
This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose,
dose-escalation study of ABL103 to evaluate the safety, tolerability, MTD (maximum tolerated
dose) and/or RP2D (recommended phase 2 dose), pharmacokinetics, immunogenicity, preliminary
antitumor activity of ABL103 in subjects with any progressive locally advanced(unresectable)
or metastatic solid tumor who are relapsed or refractory following the last line of treatment
and have no available standard of care option. This study includes 2 parts: a dose-escalation
part and tumor-expansion part